Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-187X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction ; volume:21 ; number:6 ; day:15 ; month:10 ; year:2021 ; pages:701-710 ; date:11.2021
American journal of cardiovascular drugs ; 21, Heft 6 (15.10.2021), 701-710, 11.2021
- Creator
-
Blair, Hannah A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40256-021-00503-8
- URN
-
urn:nbn:de:101:1-2022020608253331645693
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Blair, Hannah A.
- SpringerLink (Online service)
Other Objects (12)
Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
Vericiguat for Heart Failure with Reduced Ejection Fraction
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
Heart Failure with Reduced Ejection Fraction—Does Sex Matter?
SGLT2 inhibitors in heart failure with reduced ejection fraction
Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
Right ventricular ejection fraction
Genetic architecture of heart failure with preserved versus reduced ejection fraction
Anticoagulants for stroke prevention in heart failure with reduced ejection fraction
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
Vericiguat for Heart Failure with Reduced Ejection Fraction
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
Heart Failure with Reduced Ejection Fraction—Does Sex Matter?
SGLT2 inhibitors in heart failure with reduced ejection fraction
Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
Right ventricular ejection fraction
Genetic architecture of heart failure with preserved versus reduced ejection fraction
Anticoagulants for stroke prevention in heart failure with reduced ejection fraction
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
Vericiguat for Heart Failure with Reduced Ejection Fraction
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
Heart Failure with Reduced Ejection Fraction—Does Sex Matter?
SGLT2 inhibitors in heart failure with reduced ejection fraction
Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
Right ventricular ejection fraction
Genetic architecture of heart failure with preserved versus reduced ejection fraction
Anticoagulants for stroke prevention in heart failure with reduced ejection fraction